DOCSLIB.ORG

Preclinical Cushing's Syndrome Resulting from Adrenal Black

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Preclinical Cushing's Syndrome Resulting from Adrenal Black Endocrine Journal 2007, 54 (4), 543–551 Preclinical Cushing’s Syndrome Resulting from Adrenal Black Adenoma Diagnosed with Diabetic Ketoacidosis TOSHIO KAHARA, CHIKASHI SETO*, AKIO UCHIYAMA**, DAISUKE USUDA, HIROSHI AKAHORI, EIJI TAJIKA*, ATSUO MIWA**, RIKA USUDA, TAKASHI SUZUKI*** AND HIRONOBU SASANO*** Department of Internal Medicine, Toyama Prefectural Central Hospital, 2-2-78 Nishinagae, Toyama 930-8550, Japan *Department of Urology, Toyama Prefectural Central Hospital, 2-2-78 Nishinagae, Toyama 930-8550, Japan **Department of Pathology, Toyama Prefectural Central Hospital, 2-2-78 Nishinagae, Toyama 930-8550, Japan ***Department of Pathology, Tohoku University School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan Abstract. A right adrenal tumor was incidentally discovered on abdominal computed tomography performed on a 53- year-old Japanese man, who had been hospitalized with diabetic ketoacidosis. Normal values were obtained for adrenal hormones in the morning after an overnight fast and urinary cortisol excretion after treatment of diabetic ketoacidosis with insulin. However, overnight dexamethasone administration with 1 mg or 8 mg did not completely suppress serum cortisol levels. There were no remarkable physical findings related to Cushing’s syndrome. The patient was diagnosed as having preclinical Cushing’s syndrome (PCS). Histological examination of the adrenalectomy specimen demonstrated adrenal black adenoma. Blood glucose levels subsequently improved after adrenalectomy, and the patient never developed adrenal insufficiency after hydrocortisone withdrawal. The patient was treated with diet therapy alone, and maintained good glycemic control. However, the patient still showed a diabetic pattern in an oral glucose tolerance test. It seems that the existence of PCS in addition to the underlying type 2 diabetes mellitus contributed to aggravation of blood glucose levels. Although there are many aspects of the natural course of PCS that have not been thoroughly elucidated, it is necessary to remain aware that a PCS patient with abnormal glucose metabolism may develop diabetic ketoacidosis by environmental agents. Key words: Diabetic ketoacidosis, Preclinical Cushing’s syndrome, Adrenal black adenoma, Type 2 diabetes (Endocrine Journal 54: 543–551, 2007) CORTISOL excess impairs insulin action and increases adrenal incidentaloma associated with PCS have liver gluconeogenesis [1]. Eighty percent of patients demonstrated a wide spectrum in the degree of hyper- with Cushing’s syndrome have impaired glucose toler- cortisolism and autonomy [6]. The degree of glucose ance or diabetes, but these patients improve dramati- intolerance in PCS also varies greatly. cally after adrenalectomy [2]. Based on the criteria of Type 2 diabetes mellitus and other endocrine disease two or more abnormal results on classical tests of the can lead to the development of diabetic ketoacidosis in hypothalamic-pituitary-adrenal (HPA) axis, preclinical the presence of an aggravating factor, such as infection Cushing’s syndrome (PCS), is found in approximately and drinking excessive amounts of sugar-containing 6% of patients with adrenocortical incidentaloma [3], soft drinks, as well as type 1 diabetes without insulin despite the absence of typical physical findings of treatment [7, 8]. Although a patient with PCS who de- Cushing’s syndrome such as truncal obesity, moon veloped diabetic ketoacidosis has not previously been face and striae cutis [4, 5]. Studies of patients with reported in the English literature, their blood glucose levels may be exacerbated by environmental agents in addition to underlying insulin resistance due to PCS. Received: April 14, 2006 Accepted: March 8, 2007 We report a rare case of PCS resulting from adrenal Correspondence to: Toshio KAHARA, M.D., Ph.D., Department black adenoma which was diagnosed with diabetic of Internal Medicine, Toyama Prefectural Central Hospital, 2-2- ketoacidosis. 78 Nishinagae, Toyama 930-8550, Japan 544 KAHARA et al. Case Report Table 1. Laboratory data on admission [Urinalysis] A 53-year-old Japanese man had experienced thirst, pH 5 general malaise, nausea and poor appetite since the specific gravity 1.040 middle of March 2005, and had been drinking approx- Protein (2+) imately 1.5 liters of sugar-containing soft drinks per Sugar (3+) day. His symptoms gradually worsened, and body Urobilinogen (±) weight decreased 5 kg over a three-week period. Con- Bilirubin (–) sequently, he was referred to our hospital on March 29, Ketone body (3+) 2005. There was no family history of diabetes. His Occult blood (–) maximal body weight was 92 kg at 40 years old. On an [Cell blood count] oral glucose tolerance test in 1998, plasma glucose White blood cells 9900/µl levels after a 75 g oral glucose administration was Neutrophils 52.0% 102 mg/dl at fasting, 193 mg/dl at 60 minutes and 138 Eosinophils 1.0% mg/dl at 120 minutes, indicating a normal glucose tol- Lymphocytes 39.0% erance according to the diagnostic criteria of diabetes Monocytes 8.0% Red blood cells 5.61 × 106/µl mellitus by the Japan Diabetes Society (1999). He de- Hemoglobin 17.7 g/dl veloped gonarthrosis at 49 years old. Hematocrit 49.7% The patient was 180 cm tall and weighed 83 kg on Platelets 266 × 103/µl March 29, 2005. Vital signs were as follows: body temperature, 37.5 degrees; blood pressure, 134/82 [Blood chemistry] C-reactive protein 6.1 mg/dl mmHg; and regular pulse, 120/min. Other physical Total protein 8.4 g/dl examinations did not yield any remarkable findings, Alkaline phosphatase 354 IU/L including signs of Cushing’s syndrome. Laboratory Aspartate aminotransferase 14 IU/L data are summarized in Table 1, and showed a fasting Alanine aminotransferase 16 IU/L plasma glucose level of 504 mg/dl, glycosylated hemo- Lactate dehydrogenase 131 IU/L globin (HbA1c) level of 14.1%, a positive result for Total bilirubin 0.5 mg/dl urinary ketone bodies, and pH 7.169 on arterial blood γ-glutamyl transpeptidase 42 IU/L gas analysis. The patient was diagnosed with diabetic Amylase 57 IU/L ketoacidosis and was hospitalized on the same day. Creatine kinase 71 IU/L Blood urea nitrogen 15 mg/dl Initial treatment consisted of intravenous infusion of Creatinine 0.8 mg/dl regular insulin and large volumes of saline. After these Uric acid 5.7 mg/dl treatments, the patient was prescribed a 1,600 kcal/day Chloride 93 mEq/L diet in addition to subcutaneous multiple insulin injec- Sodium 133 mEq/L tion therapy. Potassium 4.6 mEq/L Anti-glutamic acid decarboxylase (GAD) antibody Total cholesterol 354 mg/dl level was less than 1.3 U/ml (Cosmic, Tokyo, Japan; Triglyceride 322 mg/dl reference range: less than 1.5 U/ml), and urinary excre- Fasting plasma glucose 504 mg/dl tion of C-peptide was 32.5 µg/day (reference range: Glycosylated hemoglobin 14.1% 32–127 µg/day). There were no diabetic complications Anti-glutamic acid decarboxylase antibody <1.3 U/ml such as neuropathy, retinopathy and nephropathy. He [Arterial blood gas analysis (room air)] underwent abdominal enhanced computed tomography pH 7.169 (CT) scan to exclude the possibility of pancreatic ma- PaCO2 11.5 mmHg lignancy. Abdominal CT scan showed a 23 mm round PaO2 124.0 mmHg mass in the right adrenal gland, but there were no ab- HCO3– 4.0 mmol/L Base excess –24.6 mmol/L normal findings in the pancreas (Fig. 1). SaO2 97.8% As shown in Table 2, the early morning levels of Anion gap 36 mEq/L serum cortisol, plasma adrenocorticotrophic hormone (ACTH), plasma aldosterone and plasma renin activity PRECLINICAL CUSHING’S SYNDROME, DIABETES 545 were all normal. Levels of urinary excretion of cortisol and 17-hydroxycorticosteroid (17-OHCS) were also within normal limits. However, the patient’s serum cortisol and ACTH levels after treatment of diabetic ketoacidosis with insulin did not show a diurnal rhythm. After overnight dexamethasone administra- tion with 1 mg and 8 mg, respectively, serum cortisol levels were not completely suppressed. Under magnetic resonance imaging (MRI), the tu- mor was hypointense compared to the liver on T1- weighted image and hyperintense compared to the liver on T2-weighted image (Fig. 2a). On chemical shift MRI, there was no reduction in signal intensity on opposed-phase images compared with that on in-phase images, indicating that the tumor was not rich in a fat component (Fig. 2b). The tumor showed homogenous contrast enhancement on dynamic enhanced study. Fig. 1. Abdominal computed tomography showed a 23 mm Adrenal scintigraphy with 131I-adosterol showed nei- round, well-circumscribed mass in the right adrenal gland. ther marked accumulation on the right adrenal region nor inhibition of the contralateral adrenal region. Clin- ical and laboratory features of the present case fulfilled Table 2. Endocrinological data (reference range) Serum ACTH 20.5 pg/ml (4.4~48.0) Cortisol 8.8 µg/dl (4.5~21.1) DHEA-S 442 ng/ml (480~2860) Plasma aldosterone concentration 47.4 pg/ml (45.0~105.5) Plasma renin activity 1.3 ng/ml/h (0.2~2.7) Adrenaline 0.062 ng/ml (<0.070) Noradrenaline 0.297 ng/ml (0.06~0.46) Dopamine <0.010 ng/ml (<0.014) Urine Vanillylmandelic acid 3.85 mg/day (1.5~4.9) Homovanillic acid 4.07 mg/day (2.4~6.0) Cortisol 64.4 µg/day (11.2~80.3) 17-KS 9.01 mg/day (4.6~18.00) 17-OHCS 7.48 mg/day (3.40~12.00) Diurnal rhythm Clock time 08:00 h 12:00 h 16:00 h 20:00 h 23:00 h ACTH (pg/ml) 20.5 23.1 18.9 20 13.9 Cortisol (µg/dl) 8.8 8.7 10.2 8.8 6.8 Dexamethasone suppression test 1mg 8mg ACTH (pg/ml) 6.9 4.5 Cortisol (µg/dl) 8.3 14.3 546 KAHARA et al.
Load more

Recommended publications
  • Ectopic Adrenocortical Adenoma in the Renal Hilum
    Liu et al. Diagnostic Pathology (2016) 11:40 DOI 10.1186/s13000-016-0490-6 CASE REPORT Open Access Ectopic adrenocortical adenoma in the renal hilum: a case report and literature review Yang Liu1,2*, Yue-Feng Jiang1,2, Ye-Lin Wang1,2, Hong-Yi Cao1,2, Liang Wang1,2, Hong-Tao Xu1,2, Qing-Chang Li1,2, Xue-shan Qiu1,2 and En-Hua Wang1,2 Abstract Background: Ectopic (accessory) adrenocortical tissue, also known as adrenal rests, is a developmental abnormality of the adrenal gland. The most common ectopic site is in close proximity to the adrenal glands and along the path of descent or migration of the gonads because of the close spatial relationship between the adrenocortical primordium and gonadal blastema during embryogenesis. Ectopic rests may undergo marked hyperplasia, and occasionally induce ectopic adrenocortical adenomas or carcinomas. Case presentation: A 27-year-old Chinese female patient who presented with amenorrhea of 3 months duration underwent computed tomography urography after ultrasound revealed a solitary mass in the left renal hilum. Histologically, the prominent eosinophilic tumor cells formed an alveolar- or acinar-like configuration. The immunohistochemical profile (alpha-inhibin+, Melan-A+, synaptophysin+) indicated the adrenocortical origin of the tumor, diagnosed as ectopic adrenocortical adenoma. The patient was alive with no tumor recurrence or metastasis at the 3-month follow-up examination. Conclusions: The unusual histological appearance of ectopic adrenocortical adenoma may result in its misdiagnosis as oncocytoma or clear cell renal cell carcinoma, especially if the specimen is limited. This case provides a reminder to pathologists to be aware of atypical cases of this benign tumor.
    [Show full text]
  • Endocrine Tumors of the Pancreas
    Friday, November 4, 2005 8:30 - 10:30 a. m. Pancreatic Tumors, Session 2 Chairman: R. Jensen, Bethesda, MD, USA 9:00 - 9:30 a. m. Working Group Session Pathology and Genetics Group leaders: J.–Y. Scoazec, Lyon, France Questions to be answered: 12 Medicine and Clinical Pathology Group leader: K. Öberg, Uppsala, Sweden Questions to be answered: 17 Surgery Group leader: B. Niederle, Vienna, Austria Questions to be answered: 11 Imaging Group leaders: S. Pauwels, Brussels, Belgium; D.J. Kwekkeboom, Rotterdam, The Netherlands Questions to be answered: 4 Color Codes Pathology and Genetics Medicine and Clinical Pathology Surgery Imaging ENETS Guidelines Neuroendocrinology 2004;80:394–424 Endocrine Tumors of the Pancreas - gastrinoma Epidemiology The incidence of clinically detected tumours has been reported to be 4-12 per million inhabitants, which is much lower than what is reported from autopsy series (about 1%) (5,13). Clinicopathological staging (12, 14, 15) Well-differentiated tumours are the large majority of which the two largest fractions are insulinomas (about 40% of cases) and non-functioning tumours (30-35%). When confined to the pancreas, non-angioinvasive, <2 cm in size, with <2 mitoses per 10 high power field (HPF) and <2% Ki-67 proliferation index are classified as of benign behaviour (WHO group 1) and, with the notable exception of insulinomas, are non-functioning. Tumours confined to the pancreas but > 2 cm in size, with angioinvasion and /or perineural space invasion, or >2mitoses >2cm in size, >2 mitoses per 20 HPF or >2% Ki-67 proliferation index, either non-functioning or functioning (gastrinoma, insulinoma, glucagonoma, somastatinoma or with ectopic syndromes, such as Cushing’s syndrome (ectopic ACTH syndrome), hypercaliemia (PTHrpoma) or acromegaly (GHRHoma)) still belong to the (WHO group 1) but are classified as tumours with uncertain behaviour.
    [Show full text]
  • C O N F E R E N C E 7 18 October 2017
    Joint Pathology Center Veterinary Pathology Services WEDNESDAY SLIDE CONFERENCE 2017-2018 C o n f e r e n c e 7 18 October 2017 CASE I: F1753191 (JPC 4101076). veterinarian revealed a regenerative anemia, stress leukogram and hypoproteinemia Signalment: 9-year-old, female intact, Rock characterized by hypoalbuminemia and the Alpine goat, Capra aegagrus hircus, goat was treated with ivermectin. caprine. Bloodwork at CSU revealed hyperglycemia and elevated creatinine, creatine kinase and History: A 9-year-old, female intact Rock aspartate aminotransferase levels. A fecal Alpine goat presented to Colorado State floatation revealed heavy loads of coccidia, University Veterinary Teaching Hospital strongyles and Trichuris spp. During a nine two months prior to necropsy with a three- day hospitalization, the doe was treated with day history of hyporexia and lethargy which intravenous fluids, kaopectate, thiamine, had progressed to lateral recumbency and fenbendazole, sulfadimethoxine, oxy- complete anorexia. The referring tetracycline and multiple blood transfusions. veterinarian had previously diagnosed the After significant improvement of her clinical doe with louse infestation, endoparasites and signs and bloodwork, including partial a heart murmur. Bloodwork by the referring resolution of the dermatitis, the doe was Haired skin goat. The skin was dry, alopecia, and covered with hyperkeratotic crusts and ulcers. (Photo courtesy of: Colorado State University, Microbiology, Immunology, and Pathology Department, College of Veterinary Medicine and Biomedical Sciences, http://csucvmbs.colostate.edu/academics/mip/Pages/default.aspx) 1 discharged. exfoliating epithelial crusts which were often tangled within scant remaining hairs. Two months later, the goat presented with a This lesion most severely affected the skin one month history of progressive scaling and over the epaxials, the ventral abdomen and ulceration over the withers, dew claws, and teats, coronary bands and dew claws.
    [Show full text]
  • 17 Endocrine Disorders T Hat Cause Diabetes
    1 7 Endocrine Disorders t hat Cause Diabetes Neil A. Hanley Endocrine Sciences Research Group, University of Manchester, Manchester, UK Keypoints • Endocrine causes of diabetes are mainly a result of an excess of • Glucagonoma and somatostatinoma are rare islet cell tumors that hormones that are counter - regulatory to insulin, and act by inhibiting produce hormones that inhibit the secretion and action of insulin. insulin secretion and/or action. • Thyrotoxicosis commonly causes mild glucose intolerance, but overt • Acromegaly is almost always secondary to growth hormone - secreting diabetes only occurs in a tiny minority. adenomas of the anterior pituitary somatotrophs and disturbs glucose • Other endocrinopathies such as primary aldosteronism and primary homeostasis in up to approximately 50% of patients. hyperparathyroidism can disturb glucose homeostasis. • Cushing syndrome is caused by excessive levels of glucocorticoids and • Polycystic ovarian syndrome occurs in 5 – 10% of women of disturbs glucose homeostasis to some degree in over 50% of cases. reproductive age and associates with some degree of glucose • Pheochromocytoma is a tumor of the chromaffi n cells, which in 90% of intolerance or diabetes resulting from insulin resistance in cases is located in the adrenal medulla and causes hyperglycemia in approximately 50% of cases. approximately 50% of cases. or a carcinoid tumor of the lung or pancreas [1] . A small percent- Introduction age of acromegaly occurs within the wider endocrine syndrome of multiple endocrine neoplasia type 1 (MEN1) caused by muta- The primary focus of this chapter is on those endocrine disorders tions in the tumor suppressor gene, MENIN [3] . MEN1 can also that cause hyperglycemia and where effective treatment of the include glucagonomas and somatostatinomas, both of which are endocrinopathy can be expected to normalize the blood glucose separately capable of causing secondary diabetes.
    [Show full text]
  • AACE Annual Meeting 2021 Abstracts Editorial Board
    June 2021 Volume 27, Number 6S AACE Annual Meeting 2021 Abstracts Editorial board Editor-in-Chief Pauline M. Camacho, MD, FACE Suleiman Mustafa-Kutana, BSC, MB, CHB, MSC Maywood, Illinois, United States Boston, Massachusetts, United States Vin Tangpricha, MD, PhD, FACE Atlanta, Georgia, United States Andrea Coviello, MD, MSE, MMCi Karel Pacak, MD, PhD, DSc Durham, North Carolina, United States Bethesda, Maryland, United States Associate Editors Natalie E. Cusano, MD, MS Amanda Powell, MD Maria Papaleontiou, MD New York, New York, United States Boston, Massachusetts, United States Ann Arbor, Michigan, United States Tobias Else, MD Gregory Randolph, MD Melissa Putman, MD Ann Arbor, Michigan, United States Boston, Massachusetts, United States Boston, Massachusetts, United States Vahab Fatourechi, MD Daniel J. Rubin, MD, MSc Harold Rosen, MD Rochester, Minnesota, United States Philadelphia, Pennsylvania, United States Boston, Massachusetts, United States Ruth Freeman, MD Joshua D. Safer, MD Nicholas Tritos, MD, DS, FACP, FACE New York, New York, United States New York, New York, United States Boston, Massachusetts, United States Rajesh K. Garg, MD Pankaj Shah, MD Boston, Massachusetts, United States Staff Rochester, Minnesota, United States Eliza B. Geer, MD Joseph L. Shaker, MD Paul A. Markowski New York, New York, United States Milwaukee, Wisconsin, United States CEO Roma Gianchandani, MD Lance Sloan, MD, MS Elizabeth Lepkowski Ann Arbor, Michigan, United States Lufkin, Texas, United States Chief Learning Officer Martin M. Grajower, MD, FACP, FACE Takara L. Stanley, MD Lori Clawges The Bronx, New York, United States Boston, Massachusetts, United States Senior Managing Editor Allen S. Ho, MD Devin Steenkamp, MD Corrie Williams Los Angeles, California, United States Boston, Massachusetts, United States Peer Review Manager Michael F.
    [Show full text]
  • Production of the a Subunit of Guanine Nucleotide-Binding Protein GO by Neuroendocrine Tumors1
    [CANCER RESEARCH 47, 5800-5805, November 1, 1987] Production of the a Subunit of Guanine Nucleotide-binding Protein GO by Neuroendocrine Tumors1 Kanefusa Kato,2 Tomiko Asano, Nobuko Kamiya, Hajime Haimoto, Syun Hosoda, Akio Nagasaka, Yutaka Ariyoshi, and Yukio Ishiguro Department of Biochemistry ¡K.K„T.A., N. K.], Institute for Developmental Research, Aichi Prefectural Colony, Kasugai, Aichi 480-03; Laboratory of Pathology ¡H.H., S. H.] and Department of Internal Medicine [Y, A.], Aichi Cancer Center, Chikusa-ku, Nagoya 464; Department of Internal Medicine [A. N.J. Fujita-Gakuen Health University, School of Medicine, Toyoake, Aichi 470-11; and Department of Surgery [Y. IJ, Nagoya University School of Medicine, Showa-ku, Nagoya 466, Japan ABSTRACT is localized exclusively in the nervous tissues and some endo crine cells in pancreas, pituitary, thyroid, and adrenal,4 which We have found that neuroendocrine tumors (including neuroblastoma, belong to a family designated as APUD (amine precursor ganglioneuroma, gut carcinoid, pheochromocytoma, medullary thyroid uptake and decarboxylation) or diffuse neuroendocrine system carcinoma, insulinoma, glucagonoma, prolactinoma, carotid body tumor, (10). We describe here the presence of G0«in tumors derived and small cell lung carcinoma) produce considerable amounts (about 1000-80,000 ng/g tissue) of the a subunit of guanine nucleotide-binding from the above mentioned neuroendocrine cells and in sera of protein, G0 (Goa), whereas nonneuroendocrine tumors contain less than patients with neuroblastoma, and evaluate G0a for the appli 300 ng of Goa/g tissue. Goat in the neuroendocrine tumors was present cation to clinical and immunohistochemical diagnosis. both in the soluble fraction, and cholate-extractable membrane-bound fraction of tissues.
    [Show full text]
  • Pancreatic Gangliocytic Paraganglioma Harboring Lymph
    Nonaka et al. Diagnostic Pathology (2017) 12:57 DOI 10.1186/s13000-017-0648-x CASEREPORT Open Access Pancreatic gangliocytic paraganglioma harboring lymph node metastasis: a case report and literature review Keisuke Nonaka1,2, Yoko Matsuda1, Akira Okaniwa3, Atsuko Kasajima2, Hironobu Sasano2 and Tomio Arai1* Abstract Background: Gangliocytic paraganglioma (GP) is a rare neuroendocrine neoplasm, which occurs mostly in the periampullary portion of the duodenum; the majority of the reported cases of duodenal GP has been of benign nature with a low incidence of regional lymph node metastasis. GP arising from the pancreas is extremely rare. To date, only three cases have been reported and its clinical characteristics are largely unknown. Case presentation: A nodule located in the pancreatic head was incidentally detected in an asymptomatic 68-year-old woman. Computed tomography revealed 18-, 8-, and 12-mm masses in the pancreatic head, the pancreatic tail, and the left adrenal gland, respectively. Subsequent genetic examination revealed an absence of mutations in the MEN1 and VHL genes. Macroscopically, the tumor located in the pancreatic head was 22 mm in size and displayed an ill-circumscribed margin along with yellowish-white color. Microscopically, it was composed of three cell components: epithelioid cells, ganglion-like cells, and spindle cells, which led to the diagnosis of GP. The tumor was accompanied by a peripancreatic lymph node metastasis. The tumor in the pancreatic tail was histologically classified as a neuroendocrine tumor (NET) G1 (grade 1, WHO 2010), whereas the tumor in the left adrenal gland was identified as an adrenocortical adenoma. The patient was disease-free at the 12-month follow-up examination.
    [Show full text]
  • Rising Incidence of Neuroendocrine Tumors
    Rising Incidence of Neuroendocrine Tumors Dasari V, Yao J, et al. JAMA Oncology 2017 S L I D E 1 Overview Pancreatic Neuroendocrine Tumors • Tumors which arise from endocrine cells of the pancreas • 5.6 cases per million – 3% of pancreatic tumors • Median age at diagnosis 60 years • More indolent course compared to adenocarcinoma – 10-year overall survival 40% • Usually sporadic but can be associated with hereditary syndromes – Core genetic pathways altered in sporadic cases • DNA damage repair (MUTYH) Chromatin remodeling (MEN1) • Telomere maintenance (MEN1, DAXX, ATRX) mTOR signaling – Hereditary: 17% of patients with germline mutation Li X, Wang C, et al. Cancer Med 2018 Scarpa A, Grimond S, et al. NatureS L I2017 D E 2 Pathology Classification European American Joint World Health Organization Neuroendocrine Committee on Cancer (WHO) Tumor Society (AJCC) (ENETS) Grade Ki-67 Mitotic rt TNM TNM T1: limit to pancreas, <2 cm T1: limit to pancreas, ≦2 cm T2: limit to pancreas, 2-4 cm T2: >limit to pancreas, 2 cm T3: limit to pancreas, >4 cm, T3: beyond pancreas, no celiac or Low ≤2% <2 invades duodenum, bile duct SMA T4: beyond pancreas, invasion involvement adjacent organs or vessels T4: involves celiac or SMA N0: node negative No: node negative Intermed 3-20% 2-20 N1: node positive N1: node positive M0: no metastases M0: no metastases High >20% >20 M1: metastases M1: metastases S L I D E 3 Classification Based on Functionality • Nonfunctioning tumors – No clinical symptoms (can still produce hormone) – Accounts for 40% of tumors – 60-85%
    [Show full text]
  • A “Tumour Trifecta:” Myelolipomata Arising Within an Adrenocortical Adenoma Ipsilateral to a Synchronous Clear Cell Renal Cell Carcinoma
    Malaysian J Pathol 2010; 32(2) : 123 – 128 CASE REPORT A “tumour trifecta:” Myelolipomata arising within an adrenocortical adenoma ipsilateral to a synchronous clear cell renal cell carcinoma. Etienne MAHE B.Sc. M.D and Ihab EL-SHINNAWY FRCPC, FCAP Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada Abstract We present an intriguing case of adrenal myelolipomata occurring within an adrenocortical adenoma in concert with an ipsilateral clear cell renal cell carcinoma. A 50-year-old female presented with dull right fl ank pain and hematuria. Computed tomography indicated a 2.5 cm right renal mass as well as a 5 cm right adrenal mass. Both masses were surgically resected concurrently. Histology of the renal mass was consistent with conventional clear cell renal cell carcinoma, Fuhrman grade III. There was no extra-renal extension or lymphovascular invasion. The adrenal mass was a cortical adenoma with solid and nested patterns, with discrete zones consisting of erythroid, myeloid and megakaryocytic cells intermixed with mature adipocytes. Mitoses were inconspicuous. The solid tumour component was strongly positive for vimentin, inhibin and CD56, focally positive for low- molecular-weight cytokeratin (Cam 5.2), calretinin and CD10 (chiefl y in the myelolipomatous zones), and negative for chromogranin, S100, HMB-45, melan-A (A103), Mart-1, synaptophysin, SMA, CK7, CK20, ER, PR, TTF-1, CD99 and GCDFP (BRST-2). Ki67 (MIB1) staining indicated a low tumour proliferation index. Although well-described individually, a search of the English language literature suggests that this is the fi rst such documented case of synchrony of these three lesions.
    [Show full text]
  • Comparative Genomic Hybridization Analysis of Thymic Neuroendocrine Tumors
    Modern Pathology (2005) 18, 358–364 & 2005 USCAP, Inc All rights reserved 0893-3952/05 $30.00 www.modernpathology.org Comparative genomic hybridization analysis of thymic neuroendocrine tumors Chin-Chen Pan1,2, Yiin-Jeng Jong3 and Yann-Jang Chen4,5 1Department of Pathology, National Yang-Ming University, Taipei, Taiwan; 2Taipei Veterans General Hospital, Taiwan; 3Institute of Genetics, National Yang-Ming University, Taipei, Taiwan; 4Faculty of Life Sciences, National Yang-Ming University, Taipei, Taiwan and 5Department of Pediatrics, Taipei Veterans General Hospital, Taiwan Thymic neuroendocrine (carcinoid) tumors are a rare neoplasm of the anterior mediastinum. The tumors frequently exhibit a wide spectrum of histology and appear to follow a more aggressive behavior than their nonthymic counterparts. Given the differing clinicopathologic manifestations, thymic neuroendocrine tumors may also possess different cytogenetic abnormalities from those that occur in foregut carcinoid tumors. In this study, we employed comparative genomic hybridization to detect genomic instability in 10 sporadic thymic neuroendocrine tumors and one multiple endocrine neoplasia type 1 (MEN1)-associated case. Gross chromosomal imbalances were found in nine cases, including gains of chromosomal material on regions X, 8, 18 and 20p and losses on 3, 6, 9q, 13q and 11q. We did not observe deletion at locus 11q13 where the MEN1 gene is located. These findings were essentially dissimilar to those reported in sporadic and MEN1-associated foregut carcinoid tumors. Consequently,
    [Show full text]
  • The Glucagonoma Syndrome And
    European Journal of Endocrinology (2004) 151 531–537 ISSN 0804-4643 REVIEW The glucagonoma syndrome and necrolytic migratory erythema: a clinical review Andre´ P van Beek, Ellen R M de Haas1, Willem A van Vloten2, Cees J M Lips3, Janine F M Roijers3 and Marijke R Canninga-van Dijk4 University Medical Center Groningen, Department of Endocrinology, PO Box 30.001, 9700 RB, Groningen, 1Erasmus MC - University Medical Center Rotterdam, Department of Dermatology, PO Box 1738, 3000 DR, Rotterdam, and Departments of 2Dermatology, 3Endocrinology and 4Pathology, University Medical Center Utrecht, PO Box 85.500, 3508 GA, Utrecht, The Netherlands (Correspondence should be addressed to A P van Beek; Email: [email protected]) Abstract The glucagonoma syndrome is a rare disease in which a typical skin disorder, necrolytic migratory erythema, is often one of the first presenting symptoms. Weight loss and diabetes mellitus are two other prevalent characteristics of this syndrome. Necrolytic migratory erythema belongs to the recently recognized family of deficiency dermatoses of which zinc deficiency, necrolytic acral erythema and pellagra are also members. It is typically characterized on skin biopsies by necrolysis of the upper epidermis with vacuolated keratinocytes. In persistent hyperglucagonemia, excessive stimulation of basic metabolic pathways results in diabetes mellitus at the expense of tissue glycogen stores, and muscle and fat mass. Multiple (essential) nutrient and vitamin B deficiencies develop, which contrib- ute to the dermatosis. In addition, glucagonomas may produce various other products, like pancreatic polypeptide, that add to the catabolic effects of glucagon. European Journal of Endocrinology 151 531–537 Introduction an appendectomy and at age 50 he was operated on because of bilateral inguinal herniae.
    [Show full text]
  • Clinical Presentation and Diagnosis of Pancreatic Neuroendocrine Tumors
    Clinical Presentation and Diagnosis of Pancreatic Neuroendocrine Tumors Carinne W. Anderson, MD*, Joseph J. Bennett, MD KEYWORDS Pancreatic neuroendocrine tumor Nonfunctional pancreatic neuroendocrine tumor Insulinoma Gastrinoma Glucagonoma VIPoma Somatostatinoma KEY POINTS Pancreatic neuroendocrine tumors are a rare group of neoplasms, most of which are nonfunctioning. Functional pancreatic neoplasms secrete hormones that produce unique clinical syndromes. The key management of these rare tumors is to first suspect the diagnosis; to do this, cli- nicians must be familiar with their clinical syndromes. Pancreatic neuroendocrine tumors (PNETs) are a rare group of neoplasms that arise from multipotent stem cells in the pancreatic ductal epithelium. Most PNETs are nonfunctioning, but they can secrete various hormones resulting in unique clinical syn- dromes. Clinicians must be aware of the diverse manifestations of this disease, as the key step to management of these rare tumors is to first suspect the diagnosis. In light of that, this article focuses on the clinical features of different PNETs. Surgical and medical management will not be discussed here, as they are addressed in other arti- cles in this issue. EPIDEMIOLOGY Classification PNETs are classified clinically as nonfunctional or functional, based on the properties of the hormones they secrete and their ability to produce a clinical syndrome. Nonfunctional PNETs (NF-PNETs) do not produce a clinical syndrome simply because they do not secrete hormones or because the hormones that are secreted do not The authors have nothing to disclose. Department of Surgery, Helen F. Graham Cancer Center, 4701 Ogletown-Stanton Road, S-4000, Newark, DE 19713, USA * Corresponding author. E-mail address: [email protected] Surg Oncol Clin N Am 25 (2016) 363–374 http://dx.doi.org/10.1016/j.soc.2015.12.003 surgonc.theclinics.com 1055-3207/16/$ – see front matter Ó 2016 Elsevier Inc.
    [Show full text]